Capricor Therapeutics CAPR Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Returns | |||||
| Return on equity | -46.6%+1.6pp | -48.2%+81.5pp | -129.6%+4.9pp | -134.5%-67.3pp | |
| Return on invested capital | -128.7%-71.6pp | -57.1%+169pp | -226.3%+340pp | -566.3%— | |
| Efficiency | |||||
| Asset turnover | 0×-0.2× | 0.2×-0.3× | 0.5×— | —— | |
| Liquidity | |||||
| Current ratio | 9×+1.2× | 7.8×+6.1× | 1.6×-0.2× | 1.8×-7.0× | |
| Leverage | |||||
| Debt-to-equity | 0×0.0× | 0×-0.2× | 0.2×-0.2× | 0.5×+0.3× | |
| Per Share | |||||
| Book value per share | $6.58+59.3% | $4.13+389% | $0.84+75.8% | $0.48-64.7% | |
| Valuation | |||||
| Market capitalization | $1.57B+150% | $627.48M+317% | $150.58M+54.5% | $97.43M+37.7% | |
| Price / book | 5.1×+0.8× | 4.3×-2.3× | 6.7×-1.6× | 8.3×+6.0× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Capricor Therapeutics's ratios come from?
- Every ratio is computed from Capricor Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.